The Oligostilbene Gnetin H Is a Novel Glycolysis Inhibitor That Regulates Thioredoxin Interacting Protein Expression and Synergizes with OXPHOS Inhibitor in Cancer Cells

• Published in: International journal of molecular sciences 2023-04, Vol.24 (9), p.7741
• Main Authors: Singh, Shivendra, De Carlo, Flavia, Ibrahim, Mohamed A, Penfornis, Patrice, Mouton, Alan J, Tripathi, Siddharth K, Agarwal, Ameeta K, Eastham, Linda, Pasco, David S, Balachandran, Premalatha, Claudio, Pier Paolo
• Format: Article
• Language: English
• Subjects: Acidification; Acids; Antineoplastic Agents; Breast cancer; Cancer; Cancer cells; Cancer therapies; Care and treatment; Cell growth; Cell Line, Tumor; Chemotherapy; Comparative analysis; Dehydrogenases; Glioblastoma; Glioblastoma cells; Glucose - metabolism; Glycolysis; gnetin H; Homeostasis; Humans; Instrument industry; International economic relations; Kinases; Lactic acid; Lung cancer; Melanoma; Metabolism; Mitochondria; Mutation; Natural products; oligostilbene; Phenformin; Physiological aspects; Protein folding; Proteins; Seeds; Thioredoxin; Thioredoxins - genetics; Thioredoxins - metabolism; Warburg effect
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms24097741

Since aerobic glycolysis was first observed in tumors almost a century ago by Otto Warburg, the field of cancer cell metabolism has sparked the interest of scientists around the world as it might offer new avenues of treatment for malignant cells. Our current study claims the discovery of gnetin H (GH) as a novel glycolysis inhibitor that can decrease metabolic activity and lactic acid synthesis and displays a strong cytostatic effect in melanoma and glioblastoma cells. Compared to most of the other glycolysis inhibitors used in combination with the complex-1 mitochondrial inhibitor phenformin (Phen), GH more potently inhibited cell growth. RNA-Seq with the T98G glioblastoma cell line treated with GH showed more than an 80-fold reduction in thioredoxin interacting protein (TXNIP) expression, indicating that GH has a direct effect on regulating a key gene involved in the homeostasis of cellular glucose. GH in combination with phenformin also substantially enhances the levels of p-AMPK, a marker of metabolic catastrophe. These findings suggest that the concurrent use of the glycolytic inhibitor GH with a complex-1 mitochondrial inhibitor could be used as a powerful tool for inducing metabolic catastrophe in cancer cells and reducing their growth.